Otsuka Holdings Co., Ltd. (FRA:OS1)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.38B +34.4% |
| Revenue (ttm) | 13.73B +5.1% |
| Net Income | 2.05B +7.3% |
| EPS | 3.89 +9.7% |
| Shares Out | n/a |
| PE Ratio | 15.28 |
| Forward PE | n/a |
| Dividend | 0.79 (1.35%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | n/a |
| Open | 59.00 |
| Previous Close | 60.50 |
| Day's Range | 59.00 - 59.00 |
| 52-Week Range | 37.60 - 63.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Otsuka Holdings
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement... [Read more]
Financial Performance
In 2025, Otsuka Holdings's revenue was 2.47 trillion, an increase of 5.97% compared to the previous year's 2.33 trillion. Earnings were 363.15 billion, an increase of 5.84%.
Financial numbers in JPY Financial StatementsNews
Otsuka Holdings Quarterly report: Q1 2026
Otsuka Holdings has published its Q1 2026 quarterly earnings report on April 28, 2026.
Otsuka Holdings Slides: Q1 2026
Otsuka Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Otsuka Holdings Quarterly report: Q4 2025
Otsuka Holdings has published its Q4 2025 quarterly earnings report on February 12, 2026.
Otsuka Holdings Slides: Q4 2025
Otsuka Holdings has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Otsuka upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Otsuka (OTSKY) to Overweight from Equal Weight with a price target of 12,600 yen, up from 9,000 yen. The stock currently prices in peak sales of Voyxact…
US FDA approves Otsuka's kidney disease drug
The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator's website showed on Tuesday.
Otsuka Holdings Quarterly report: Q3 2025
Otsuka Holdings has published its Q3 2025 quarterly earnings report on October 31, 2025.
Otsuka Holdings Slides: Q3 2025
Otsuka Holdings has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 31, 2025.
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...
Otsuka Holdings Quarterly report: Q2 2025
Otsuka Holdings has published its Q2 2025 quarterly earnings report on July 31, 2025.
Otsuka Holdings Slides: Q2 2025
Otsuka Holdings has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 31, 2025.
Vera Therapeutics drops 30% after rival Otsuka presents Phase 3 data
Shares of Vera Therapeutics (VERA) dropped nearly 30% in premarket trading after rival Otsuka (OTSKY) presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study evaluating ...
Otsuka initiated with a Market Perform at Bernstein
Bernstein analyst Miki Sogi initiated coverage of Otsuka (OTSKY) with a Market Perform rating. The firm believes the current stock price appropriately reflects “what is likely to come.” Published firs...
Otsuka downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Chikai Tanaka downgraded Otsuka (OTSKY) to Sell from Neutral with a 3,110 yen price target The company’s strong earnings looks priced into the shares while its fiscal…
iBio to sell preclinical PD-1 agonist antibody program to Otsuka
iBio (IBIO) entered into an asset purchase agreement with Otsuka Pharmaceutical Co., (OTSKY), pursuant to which Otsuka acquired iBio’s assets related to its early-stage programmed cell death protein 1...